Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlifidase in ANCA-associated vasculitis with severe diffuse alveolar hemorrhage
2024-516727-13-00Phase 2Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Oct 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efgartigimod alfa in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: ANCA seroconversion within 24 hours. Planned start Oct 2024; status: authorised.
02
Drugs
efgartigimod alfa
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on 2024-516727-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516727-13-00.